Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes
- Moumita SarkarAffiliated withThe Motherisk ProgramDivision of Clinical Pharmacology, The Hospital for Sick Children Email author
- , Gideon KorenAffiliated withThe Motherisk Program
- , Sanjog KalraAffiliated withThe Motherisk Program
- , Angela YingAffiliated withThe Motherisk Program
- , Carlo SmorlesiAffiliated withServicio di Tossicologica Perinatale
- , Marco De SantisAffiliated withTelefono Rosso
- , Orna Diav-CitrinAffiliated withIsrael Teratogen Information
- , Meytal AvgilAffiliated withIsrael Teratogen Information
- , Sharon Voyer LavigneAffiliated withConnecticut Pregnancy Riskline
- and 2 more
- , Matti BerkovichAffiliated withTel Aviv University
- , Adrienne EinarsonAffiliated withThe Motherisk Program
- Show less
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Montelukast (Singulair) is a selective leukotriene receptor antagonist (LTRA) indicated for the maintenance treatment of asthma. Currently, there are limited prospective, comparative studies in the literature examining the safety of montelukast use in pregnancy.
The primary objective of this study was to determine whether exposure to montelukast during pregnancy increases the rate of major malformations above the 1–3% baseline risk or the rate of other adverse effects.
Pregnant women taking montelukast were enrolled in the study from six teratogen information services around the world. These women were compared to two other groups of women: (1) disease-matched, who used inhalers for a similar indication and (2) women not diagnosed with asthma and not exposed to any known teratogens. The primary outcome was major malformations and secondary endpoints included spontaneous abortion, fetal distress, gestational age at birth and birth weight.
Out of 180 montelukast-exposed pregnancies, there were 160 live births including three sets of twins, 20 spontaneous abortions, 2 elective abortions and 1 major malformation reported. The mean birth weight was lower (3,214 ± 685 g) compared to controls [3,356 ± 657 (disease-matched) and 3,424 ± 551 (exposed to non-teratogens), P = 0.038] and the gestational age was shorter [37.8 ± 3.1 weeks (montelukast) and 37.6 ± 4.4 (disease-matched) versus 39.3 ± 2.4 weeks (exposed to non-teratogens), P = 0.045]. About 25% of the newborns had fetal distress, a higher rate than controls (P = 0.007). However, upon sub-analysis of women who continued the drug until delivery, only birth-weight difference (304 g) remained significant.
Montelukast does not appear to increase the baseline rate of major malformations. The lower birth weight in both asthma groups is most likely associated with the severity of the maternal condition.
KeywordsAsthma Malformations Pregnancy Montelukast Preterm delivery Low birth weight
- Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes
European Journal of Clinical Pharmacology
Volume 65, Issue 12 , pp 1259-1264
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Preterm delivery
- Low birth weight
- Industry Sectors
- Author Affiliations
- 1. The Motherisk Program, Toronto, Canada
- 7. Division of Clinical Pharmacology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G1X8, Canada
- 2. Servicio di Tossicologica Perinatale, Firenze, Italy
- 3. Telefono Rosso, Rome, Italy
- 4. Israel Teratogen Information, Jerusalem, Israel
- 5. Connecticut Pregnancy Riskline, West Hartford, CT, USA
- 6. Tel Aviv University, Tel Aviv, Israel